Anika Therapeutics | ANIK - Interest Expense On Debt


Anika Therapeutics reported 189.44M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Abbott USD 42M 2M Dec/2025
Agenus USD 16.02M 2.85M Dec/2025
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Anika Therapeutics 189.44M 1.76M Sep/2025
Arrowhead Research USD 22.5M 811K Dec/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 20.6M 217K Dec/2025
Integra LifeSciences USD 23.67M 953K Dec/2025
Intrexon USD 2K 5K Jun/2024
J&J USD 18M 290M Sep/2025
Karyopharm Therapeutics USD 11.38M 2.43M Sep/2024
Ligand Pharmaceuticals USD 910K 243K Sep/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Merit Medical Systems USD 6.36M 390K Dec/2025
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR -25M 252M Dec/2025
Smith & Nephew USD 69M 1000K Dec/2025
Stryker USD 157M 46.17B Sep/2025
Surmodics USD 884K 5K Sep/2024
Veracyte USD 2K 1000 Dec/2023
Xencor USD 7.35M 311K Dec/2025
Zimmer Biomet Holdings USD 71.9M 3.5M Dec/2025